1-BOC-3-甲基吡唑-5-硼酸 | 1217501-27-3

• 物质功能分类: 化学试剂 - 有机试剂 - 硼酸
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1-BOC-3-甲基吡唑-5-硼酸
• 英文名称: (1-(tert-butoxycarbonyl)-3-methyl-1H-pyrazol-5-yl)boronic acid
• 英文别名: [5-methyl-2-[(2-methylpropan-2-yl)oxycarbonyl]pyrazol-3-yl]boronic acid
• CAS: 1217501-27-3
• 化学式: C₉H₁₅BN₂O₄
• 分子量: 226.04
• InChiKey: JCGANVBFCXPIOL-UHFFFAOYSA-N

物化性质

• 沸点：
  394.5±52.0 °C(Predicted)
• 密度：
  1.19±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.35
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  84.6
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  10-bromo-9-fluoro-3-iodo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine-2-carboxamide 、 1-BOC-3-甲基吡唑-5-硼酸 以to produce crude 10-bromo-9-fluoro-3-(3-methyl-1H-pyrazol-5-yl)-5,6 dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine-2-carboxamide的产率得到10-bromo-9-fluoro-3(3-methyl-1H-pyrazol-5-yl)-5,6 dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine-2-carboxamide
  参考文献：
  名称：

  Tricyclic compounds and methods of use therefor

  摘要：

  本发明涉及式I的新化合物：其中A1，A2，A3，A4，A5，A6，R2，R4，R5，R6，R7，R8和下标m和n的含义如此处所述。式I的化合物及其制备的药物组合物在治疗疾病和障碍方面是有用的，其中观察到NF-kB信号的不良或过度激活。

  公开号：

  US09034866B2

文献信息

• Substituted imidazo[1,2-a]pyrimidines and —pyridines
  申请人：Ince Stuart

  公开号：US08975265B2

  公开（公告）日：2015-03-10

  Compounds of formula (I) which are effective inhibitors of the Pi3K/Akt pathway, processes for their production and their use as pharmaceuticals.

  式(I)的化合物是Pi3K/Akt通路的有效抑制剂，其制备过程以及它们作为药物的用途。
• Substituted Imidazo[1,2-a]pyrimidines and -pyridines
  申请人：Ince Stuart

  公开号：US20130190332A1

  公开（公告）日：2013-07-25

  Compounds of formula (I) which are effective inhibitors of the Pi3K/Akt pathway, processes for their production and their use as pharmaceuticals.

  式(I)化合物是有效的Pi3K/Akt通路抑制剂，其制备过程和作为药物的用途。
• Tricyclic compounds and methods of use therefor
  申请人：Genentech, Inc.

  公开号：US09034866B2

  公开（公告）日：2015-05-19

  The invention relates to novel compounds of Formula I: wherein A1, A2, A3, A4, A5, A6, R2, R4, R5, R6, R7, R8 and subscripts m and n each has the meaning as described herein. Compounds of Formula I and pharmaceutical compositions thereof are useful in the treatment of disease and disorders in which undesired or over-activation of NF-kB signaling is observed.

  本发明涉及式I的新化合物：其中A1，A2，A3，A4，A5，A6，R2，R4，R5，R6，R7，R8和下标m和n的含义如此处所述。式I的化合物及其制备的药物组合物在治疗疾病和障碍方面是有用的，其中观察到NF-kB信号的不良或过度激活。
• SUBSTITUTED 6-ARYL-IMIDAZOPYRIDINE AND 6-ARYL-TRIAZOLOPYRIDINE CARBOXAMIDE ANALOGS AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR5
  申请人：Vanderbilt University

  公开号：US20160096833A1

  公开（公告）日：2016-04-07

  Disclosed are negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention

  本发明揭示了代谢型谷氨酸受体亚型5（mGluR5）的负向变构调节剂；制备该化合物的合成方法；包含该化合物的药物组合物；以及使用该化合物和组合物治疗与谷氨酸功能障碍相关的神经和精神障碍的方法。此摘要旨在作为特定领域搜索的扫描工具，不旨在限制本发明。
• TRICYCLIC COMPOUNDS AND METHODS OF USE THEREFOR
  申请人：Genentech, Inc.

  公开号：US20130217666A1

  公开（公告）日：2013-08-22

  The invention relates to novel compounds of Formula I: wherein A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , R 2 , R 4 , R 5 , R 6 , R 7 , R 8 and subscripts m and n each has the meaning as described herein. Compounds of Formula I and pharmaceutical compositions thereof are useful in the treatment of disease and disorders in which undesired or over-activation of NF-kB signaling is observed.

  本发明涉及公式I的新化合物：其中A1，A2，A3，A4，A5，A6，R2，R4，R5，R6，R7，R8和下标m和n的含义如此处所述。公式I的化合物及其制药组合物在治疗观察到NF-kB信号不良或过度激活的疾病和障碍方面是有用的。